<DOC>
	<DOCNO>NCT00003768</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness combretastatin A4 phosphate treat patient advance solid tumor respond previous therapy .</brief_summary>
	<brief_title>Combretastatin A4 Phosphate Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose combretastatin A4 phosphate administer single dos every 21 day patient advance solid tumor . II . Determine toxicity dose limit toxicity regimen patient . III . Determine plasma urine pharmacokinetics combretastatin A4 combretastatin A4 phosphate . IV . Gather preliminary data regard possible antitumor effect patient measurable disease . OUTLINE : This open label , dose escalation study . Patients receive combretastatin A4 phosphate IV 10-60 minute . Treatment repeat every 3 week absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos combretastatin A4 phosphate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow 3 week . PROJECTED ACCRUAL : A maximum 21 patient accrue study .</detailed_description>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven advanced solid tumor fail standard therapy curative therapy exist No leukemia , lymphoma , multiple myeloma No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin normal SGOT/SGPT great 3 time upper limit normal ( ULN ) PT/PTT le ULN OR International normalize ratio ( INR ) less 1.1 Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No clear evidence acute ischemic heart disease EKG No history myocardial infarction within past 6 month No history angina No peripheral vascular disorder Neurologic : No active seizure disorder Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence hematemesis , melena , hematochezia No history inflammatory bowel disease , autoimmune disease , bleed disorder No Type I diabetes mellitus Type II diabetes peripheral vascular disorder No active infection serious concurrent systemic disorder incompatible study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : At least 6 week since prior major surgery Other : At least 4 week since prior investigational agent No concurrent anticonvulsant therapy No concurrent aspirin great 100 mg per day , heparin , nonsteroidal antiinflammatory medication No concurrent calcium channel blocker , antiarrhythmias , antiangina therapy Concurrent betablocking agent hypertension anxiety allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>